382129
HIV Reverse Transcriptase, Recombinant, E. coli
liquid, ≥5,000 units/mg protein, Nuclease-free
Sinónimos:
HIV RT
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
recombinant
expressed in E. coli
Quality Level
form
liquid
specific activity
≥10,000 units/mL
≥5,000 units/mg protein
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
technique(s)
molecular cloning: suitable
foreign activity
Nuclease-free
shipped in
wet ice
storage temp.
−20°C
General description
Recombinant HIV reverse transcriptase expressed in E. coli. Catalyzes error-prone synthesis on DNA and RNA templates. Provides an excellent target for evaluating antiviral agents.
Application
HIV Reverse Transcriptase, Recombinant, E.coli has been used as a standard in reverse transcriptase activity assay.
Packaging
Please refer to vial label for lot-specific concentration.
Warning
Toxicity: Standard Handling (A)
Unit Definition
One unit is defined as the amount of enzyme that will incorporate 1.0 nmol of labeled dTTP into acid-insoluble material in 20 min at 37°C, pH 8.3.
Physical form
In 10 mM potassium phosphate, 1 mM DTT, 20% glycerol, pH 7.4.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
mBio, e0275221-e0275221 (2022-01-12)
Infection of rhesus macaques with simian-human immunodeficiency viruses (SHIVs) is the preferred model system for vaccine development because SHIVs encode human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Envs)-a key target of HIV-1 neutralizing antibodies. Since the goal of vaccines
Journal of virology, 95(3) (2020-11-06)
Given the projected increase in multidrug-resistant HIV-1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host-targeting compounds are of particular interest because they can offer
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico